The FDA has warned Sanofi about significant deviations from Current Good Manufacturing Practice regulations for active pharmaceutical ingredients.

Sanofi is following in the footsteps of a number of its peers in pharma with a plan to spin off its consumer health business into a separate company and focus its efforts on its prescription drugs ...